BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 32557398)

  • 1. Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation.
    Motta I; Bou-Fakhredin R; Taher AT; Cappellini MD
    Drugs; 2020 Jul; 80(11):1053-1063. PubMed ID: 32557398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New therapeutic targets in transfusion-dependent and -independent thalassemia.
    Cappellini MD; Motta I
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):278-283. PubMed ID: 29222267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging therapies in β-thalassemia: toward a new era in management.
    Bou-Fakhredin R; Tabbikha R; Daadaa H; Taher AT
    Expert Opin Emerg Drugs; 2020 Jun; 25(2):113-122. PubMed ID: 32249632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beta Thalassemia: Monitoring and New Treatment Approaches.
    Khandros E; Kwiatkowski JL
    Hematol Oncol Clin North Am; 2019 Jun; 33(3):339-353. PubMed ID: 31030806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent Progress in Gene Therapy and Other Targeted Therapeutic Approaches for Beta Thalassemia.
    Hamed EM; Meabed MH; Aly UF; Hussein RRS
    Curr Drug Targets; 2019; 20(16):1603-1623. PubMed ID: 31362654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging Therapies in β-Thalassemia.
    Bou-Fakhredin R; Kuo KHM; Taher AT
    Hematol Oncol Clin North Am; 2023 Apr; 37(2):449-462. PubMed ID: 36907614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unmet needs in β-thalassemia and the evolving treatment landscape.
    Njeim R; Naouss B; Bou-Fakhredin R; Haddad A; Taher A
    Transfus Clin Biol; 2024 Feb; 31(1):48-55. PubMed ID: 38128605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of transfusion-dependent β-thalassemia (TDT): Expert insights and practical overview from the Middle East.
    El-Beshlawy A; Dewedar H; Hindawi S; Alkindi S; Tantawy AA; Yassin MA; Taher AT
    Blood Rev; 2024 Jan; 63():101138. PubMed ID: 37867006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2021 update on clinical trials in β-thalassemia.
    Musallam KM; Bou-Fakhredin R; Cappellini MD; Taher AT
    Am J Hematol; 2021 Nov; 96(11):1518-1531. PubMed ID: 34347889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beta-thalassemia and the advent of new interventions beyond transfusion and iron chelation.
    Chauhan W; Shoaib S; Fatma R; Zaka-Ur-Rab Z; Afzal M
    Br J Clin Pharmacol; 2022 Aug; 88(8):3610-3626. PubMed ID: 35373382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Αlpha-thalassemia: A practical overview.
    Musallam KM; Cappellini MD; Coates TD; Kuo KHM; Al-Samkari H; Sheth S; Viprakasit V; Taher AT
    Blood Rev; 2024 Mar; 64():101165. PubMed ID: 38182489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How I treat non-transfusion-dependent β-thalassemia.
    Saliba AN; Musallam KM; Taher AT
    Blood; 2023 Sep; 142(11):949-960. PubMed ID: 37478396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-Transfusion-Dependent Thalassemia: A Panoramic Review.
    Shash H
    Medicina (Kaunas); 2022 Oct; 58(10):. PubMed ID: 36295656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Current management of thalassemia intermedia].
    Thuret I
    Transfus Clin Biol; 2014 Nov; 21(4-5):143-9. PubMed ID: 25282488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. β-Thalassemia intermedia: a comprehensive overview and novel approaches.
    Asadov C; Alimirzoeva Z; Mammadova T; Aliyeva G; Gafarova S; Mammadov J
    Int J Hematol; 2018 Jul; 108(1):5-21. PubMed ID: 29380178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increasing prevalence of thalassemia in America: Implications for primary care.
    Sayani FA; Kwiatkowski JL
    Ann Med; 2015; 47(7):592-604. PubMed ID: 26541064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iron overload in β-thalassemia intermedia: an emerging concern.
    Musallam KM; Cappellini MD; Taher AT
    Curr Opin Hematol; 2013 May; 20(3):187-92. PubMed ID: 23426199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thalassemia.
    Aydinok Y
    Hematology; 2012 Apr; 17 Suppl 1():S28-31. PubMed ID: 22507773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
    Kontoghiorghe CN; Kontoghiorghes GJ
    Drug Des Devel Ther; 2016; 10():465-81. PubMed ID: 26893541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent trends in treatment of thalassemia.
    El-Beshlawy A; El-Ghamrawy M
    Blood Cells Mol Dis; 2019 May; 76():53-58. PubMed ID: 30792169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.